Linked Life Data

19873981

Source:http://linkedlifedata.com/resource/pubmed/id/19873981

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19873981rdf:typepubmed:Citationlld:pubmed
pubmed-article:19873981lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C0032405lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:19873981lifeskim:mentionsumls-concept:C2744441lld:lifeskim
pubmed-article:19873981pubmed:issue22lld:pubmed
pubmed-article:19873981pubmed:dateCreated2009-11-20lld:pubmed
pubmed-article:19873981pubmed:abstractTextWe disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC(50) = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC(50) = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC(50) in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.lld:pubmed
pubmed-article:19873981pubmed:languageenglld:pubmed
pubmed-article:19873981pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:citationSubsetIMlld:pubmed
pubmed-article:19873981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19873981pubmed:statusMEDLINElld:pubmed
pubmed-article:19873981pubmed:monthNovlld:pubmed
pubmed-article:19873981pubmed:issn1520-4804lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:LamartinaStef...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:RoscilliGiuse...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:ToniattiCarlo...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:AltamuraSergi...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:RowleyMichael...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:JonesPhilipPlld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:OntoriaJesus...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:PesciSilviaSlld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:MonteagudoEdi...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:PalumbiMaria...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:GiominiClaudi...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:ScarpelliRita...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:FonsiMassimil...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:Schultz-Fadem...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:FerrignoFeder...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:OrsaleMaria...lld:pubmed
pubmed-article:19873981pubmed:authorpubmed-author:BoueresJuliaJlld:pubmed
pubmed-article:19873981pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19873981pubmed:day26lld:pubmed
pubmed-article:19873981pubmed:volume52lld:pubmed
pubmed-article:19873981pubmed:ownerNLMlld:pubmed
pubmed-article:19873981pubmed:authorsCompleteYlld:pubmed
pubmed-article:19873981pubmed:pagination7170-85lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:meshHeadingpubmed-meshheading:19873981...lld:pubmed
pubmed-article:19873981pubmed:year2009lld:pubmed
pubmed-article:19873981pubmed:articleTitleDiscovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.lld:pubmed
pubmed-article:19873981pubmed:affiliationIRBM/Merck Research Labs Rome, Via Pontina km 30,600, 00040 Pomezia, Italy. philip_jones@merck.comlld:pubmed
pubmed-article:19873981pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:19873981lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19873981lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19873981lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19873981lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19873981lld:pubmed